Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 13/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 13/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 13/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 12/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 10/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1109790 | 1.00 | CHRM3 (0.41) | CHRM3POLBCHRM2CHRM1CHRM4 | |
| SCHEMBL1109782 | 1.00 | CHRM3 (0.41) | CHRM3POLBCHRM2CHRM1CHRM4 | |
| SCHEMBL3225415 | 1.00 | CHRM3 (0.41) | CHRM3POLBCHRM2CHRM1CHRM4 | |
| SCHEMBL4739830 | 1.00 | CHRM3 (0.41) | CHRM3POLBCHRM2CHRM1CHRM4 | |
| SCHEMBL1109822 | 0.99 | ALDH1A1 (0.40) | CHRM3POLBCHRM2CHRM1CHRM4 | |
| SCHEMBL3218882 | 0.99 | ALDH1A1 (0.40) | CHRM3POLBCHRM2CHRM1CHRM4 | |
| SCHEMBL13329443 | 0.99 | ALDH1A1 (0.40) | CHRM3POLBCHRM2CHRM1CHRM4 | |
| SCHEMBL3202857 | 0.96 | ATM (0.39) | CHRM3POLBCHRM2CHRM1CHRM4 | |
| SCHEMBL1109856 | 0.88 | POLB (0.44) | CHRM3POLBCHRM2CHRM1CHRM4 | |
| SCHEMBL1109796 | 0.87 | CHRM3 (0.39) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101636390-B | Napadisylate salt of a muscarinic M3 antagonist | ARGENTA DISCOVERY LTD GB | 2013-06-12 | — | — | CN | disclosed |
| US-20120277275-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-11-01 | — | — | US | disclosed |
| US-20120277275-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-11-01 | — | — | US | disclosed |
| US-20120277275-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-11-01 | — | — | US | disclosed |
| CN-101678005-B | Combination of a muscarinic receptor antagonist and a beta-2 adrenergic receptor agonist | ARGENTA DISCOVERY LTD | 2012-10-31 | — | — | CN | disclosed |
| CN-101282949-B | Azole and thiazole derivatives and uses thereof | ARGENTA DISCOVERY LTD | 2012-05-23 | — | — | CN | disclosed |
| US-20110046191-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ARGENTA DISCOVERY LTD. (GB) | 2011-02-24 | — | — | US | disclosed |
| US-20110046191-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ARGENTA DISCOVERY LTD. (GB) | 2011-02-24 | — | — | US | disclosed |
| US-20110046191-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ARGENTA DISCOVERY LTD. (GB) | 2011-02-24 | — | — | US | disclosed |
| EP-2280006-A1 | PHARMACEUTICAL COMPOSITION FOR INHALATION COMPRISING AN OXAZOLE OR THIAZOLE M3 MUSCARINIC RECEPTOR ANTAGONIST | Pulmagen Therapeutics (Synergy) Limited (GB) | 2011-02-02 | — | — | EP | disclosed |
| WO-2008096136-A1 | COMBINATIONS WITH A MUSCARINIC RECEPTOR ANTAGONIST | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096126-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096126-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096136-A1 | COMBINATIONS WITH A MUSCARINIC RECEPTOR ANTAGONIST | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096128-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AND THEIR USES 2 | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096143-A1 | NAPADISYLATE SALT OF A MUSCARINIC M3 ANTAGONIST | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096128-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AND THEIR USES 2 | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | disclosed |
| EP-1924570-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | Argenta Discovery Limited (GB) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007017669-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | ARGENTA DISCOVERY LTD. (GB) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007017669-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | ARGENTA DISCOVERY LTD. (GB) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277275-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | CHRM3, GPR65, GPR34 | CHRM3 1/4885POLB 4612/4885CHRM2 12/4885 |
| US-20110046191-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ADRB2, ADRB1, ADRA2A | CHRM3 11/4885POLB 2442/4885CHRM2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.